JP2020533971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533971A5 JP2020533971A5 JP2020511477A JP2020511477A JP2020533971A5 JP 2020533971 A5 JP2020533971 A5 JP 2020533971A5 JP 2020511477 A JP2020511477 A JP 2020511477A JP 2020511477 A JP2020511477 A JP 2020511477A JP 2020533971 A5 JP2020533971 A5 JP 2020533971A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- cells
- soluble
- protein complex
- soluble fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551218P | 2017-08-28 | 2017-08-28 | |
| US62/551,218 | 2017-08-28 | ||
| PCT/US2018/048365 WO2019046313A1 (en) | 2017-08-28 | 2018-08-28 | IL-15 BASED FUSIONS WITH IL-7 AND IL-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533971A JP2020533971A (ja) | 2020-11-26 |
| JP2020533971A5 true JP2020533971A5 (cg-RX-API-DMAC7.html) | 2021-10-07 |
Family
ID=65526059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511477A Withdrawn JP2020533971A (ja) | 2017-08-28 | 2018-08-28 | Ｉｌ−１５をベースとするｉｌ−７及びｉｌ−２１への融合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11161890B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3676289A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020533971A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200090742A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111655716B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018323455B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3074635A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019046313A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5501222B2 (ja) * | 2007-05-11 | 2014-05-21 | アルター・バイオサイエンス・コーポレーション | 融合分子及びｉｌ−１５変異体 |
| JP7136454B2 (ja) * | 2017-01-20 | 2022-09-13 | 国立大学法人京都大学 | ＣＤ８α＋β＋細胞傷害性Ｔ細胞の製造方法 |
| CA3216726C (en) | 2017-03-06 | 2025-08-05 | Altor Bioscience Corporation | IL-15-BASED FUSION PROTEINS SPECIFIC TO IL-12 AND IL-18 |
| AU2018323455B2 (en) | 2017-08-28 | 2022-02-03 | Altor Bioscience, Llc | IL-15-based fusions to IL-7 and IL-21 |
| WO2020037120A1 (en) * | 2018-08-16 | 2020-02-20 | Nantbio, Inc. | Il7-il15 txm compositions and methods |
| EP4659757A2 (en) | 2018-08-30 | 2025-12-10 | ImmunityBio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CA3109361A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| JP7407822B2 (ja) | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 単鎖キメラポリペプチドおよびその使用 |
| GB201818816D0 (en) * | 2018-11-19 | 2019-01-02 | Synpromics Ltd | Regulatory nucleic acid sequences |
| CN111825770B (zh) * | 2019-04-16 | 2023-06-09 | 成都医学院 | 长效白介素21-Fc融合蛋白及其用途 |
| CN114269903B (zh) | 2019-06-21 | 2025-11-25 | 免疫生物公司 | 多链嵌合多肽和其用途 |
| GB201909144D0 (en) | 2019-06-25 | 2019-08-07 | Autolus Ltd | Culture medium |
| US11453862B2 (en) | 2019-07-08 | 2022-09-27 | Immunitybio, Inc. | Mononuclear cell derived NK cells |
| WO2021006875A1 (en) * | 2019-07-08 | 2021-01-14 | Nantkwest, Inc. | Mononuclear cell derived nk cells |
| WO2021041886A1 (en) * | 2019-08-29 | 2021-03-04 | Nantbio, Inc. | Modified n-810 and methods therefor |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| US12115191B2 (en) | 2020-02-11 | 2024-10-15 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| AU2021219720B2 (en) | 2020-02-11 | 2025-10-02 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| US12398189B2 (en) | 2020-02-11 | 2025-08-26 | HCW Biologics, Inc. | Methods of activating regulatory T cells |
| JP7734693B2 (ja) | 2020-04-29 | 2025-09-05 | イミュニティーバイオ インコーポレイテッド | 抗ｃｄ２６タンパク質及びそれらの使用法 |
| CA3184756A1 (en) * | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) * | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| GB202008957D0 (en) | 2020-06-12 | 2020-07-29 | Autolus Ltd | Culture medium |
| EP4232071A4 (en) | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| CA3219181A1 (en) | 2021-05-19 | 2022-11-24 | Yik Andy Yeung | Il-21 polypeptides and targeted constructs |
| EP4351320A1 (en) | 2021-06-09 | 2024-04-17 | ImmunityBio, Inc. | Methods and systems for producing a protein of interest in a plant |
| WO2023278693A1 (en) * | 2021-06-30 | 2023-01-05 | The Regents Of The University Of California | Altering cytokine specificity through binding valency |
| CN113549158B (zh) * | 2021-07-19 | 2022-10-21 | 广州百暨基因科技有限公司 | 包含突变型il15以及嵌合抗原受体的融合蛋白 |
| CN119546343A (zh) * | 2022-04-27 | 2025-02-28 | 亚设生物治疗公司 | 细胞因子融合蛋白与cd8抗原结合分子的组合 |
| WO2024040132A2 (en) * | 2022-08-16 | 2024-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Synergistic interactions for improved cancer treatment |
| WO2024193705A1 (en) * | 2023-03-23 | 2024-09-26 | Analytical Biosciences Shanghai Limited | Tnf superfamily member immunocytokine and uses thereof |
| CN117186243B (zh) * | 2023-07-26 | 2025-08-19 | 四川三优康生物技术有限公司 | 猪白细胞介素15，21和23共表达生物制剂材料及应用 |
| WO2025064822A2 (en) * | 2023-09-20 | 2025-03-27 | Factor Bioscience Inc. | Cells and methods for engineering cells with persistent transgene expression |
| CN117050178B (zh) * | 2023-10-13 | 2024-01-12 | 北京百普赛斯生物科技股份有限公司 | 特异性检测il-7的抗体及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507A (en) | 1851-11-11 | petess | ||
| US222A (en) | 1837-06-10 | Truss for the retention and radical cure qe hernia | ||
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| AU5098393A (en) | 1992-08-14 | 1994-03-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant toxin with increased half-life |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5534592A (en) | 1995-09-22 | 1996-07-09 | The Goodyear Tire & Rubber Company | High performance blend for tire treads |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| AU2004289316B2 (en) | 2003-11-10 | 2011-03-31 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| JP5501222B2 (ja) * | 2007-05-11 | 2014-05-21 | アルター・バイオサイエンス・コーポレーション | 融合分子及びｉｌ−１５変異体 |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| EP2918607B1 (en) * | 2010-09-21 | 2017-11-08 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| US9724393B2 (en) | 2015-10-06 | 2017-08-08 | The Wistar Institute Of Anatomy And Biology | Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation |
| CA3200275A1 (en) | 2016-10-21 | 2018-04-26 | Nantcell, Inc. | Multimeric il-15-based molecules |
| AU2018323455B2 (en) | 2017-08-28 | 2022-02-03 | Altor Bioscience, Llc | IL-15-based fusions to IL-7 and IL-21 |
-
2018
- 2018-08-28 AU AU2018323455A patent/AU2018323455B2/en active Active
- 2018-08-28 CA CA3074635A patent/CA3074635A1/en not_active Abandoned
- 2018-08-28 US US16/114,870 patent/US11161890B2/en active Active
- 2018-08-28 JP JP2020511477A patent/JP2020533971A/ja not_active Withdrawn
- 2018-08-28 EP EP18851494.7A patent/EP3676289A4/en active Pending
- 2018-08-28 CN CN201880070462.7A patent/CN111655716B/zh active Active
- 2018-08-28 KR KR1020207009046A patent/KR20200090742A/ko not_active Ceased
- 2018-08-28 WO PCT/US2018/048365 patent/WO2019046313A1/en not_active Ceased
-
2021
- 2021-10-18 US US17/504,100 patent/US11965007B2/en active Active
-
2023
- 2023-09-21 US US18/472,053 patent/US12410224B2/en active Active
-
2024
- 2024-07-17 US US18/775,868 patent/US20240368237A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533971A5 (cg-RX-API-DMAC7.html) | ||
| US10428119B2 (en) | Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes | |
| AU2007271398B2 (en) | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses | |
| JP2023123877A (ja) | 養子細胞療法のための腫瘍浸潤リンパ球 | |
| JP2020508691A5 (cg-RX-API-DMAC7.html) | ||
| CN110198737A (zh) | 靶向psma的三特异性蛋白质及使用方法 | |
| JP2005520853A (ja) | 蛋白質ワクチン接種の有効なアジュバントとしての抗体融合蛋白質 | |
| AU2012268013A1 (en) | Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes | |
| HU219680B (hu) | Tumorellenes hatású ellenanyag-konjugátumok, eljárás előállításukra és a konjugátumokat tartalmazó gyógyászati készítmények | |
| Debets et al. | Cytokine antagonists and their potential therapeutic use | |
| US20070003514A1 (en) | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination | |
| KR102578682B1 (ko) | Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells) | |
| Debinski et al. | Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas | |
| CN119264269A (zh) | 结合cd19的嵌合抗原受体及其用途 | |
| ES2358118T3 (es) | Procedimiento para la obtención de anticuerpos humanos que neutralizan la actividad biológica de una citoquina humana. | |
| Helguera et al. | Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors | |
| Selinsky et al. | Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo | |
| CA3198822A1 (en) | Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides | |
| WO2021092719A1 (zh) | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 | |
| CA3088343A1 (en) | Combination therapy for treating or preventing cancer | |
| WO2003045997A2 (en) | Fusion proteins containing tlp peptides | |
| RU2024116904A (ru) | Улучшенные антигенсвязывающие рецепторы | |
| US20090148440A1 (en) | Antibodies against interleukin-22 binding protein and its uses for the treatment of metabolic disorders | |
| CN119367516A (zh) | 一种免疫调节因子组合物及其应用 | |
| KR101286065B1 (ko) | 항-Ｈｅｒ-2／ｎｅｕ 키메라 면역 수용체를 발현하는 사이토카인 유도 살해세포, 이를 포함하는 약제학적 조성물 및 이를 이용한 종양 치료 방법 |